Ind-Swift Laboratories Limited
Momentum (100/100) does the heavy lifting; financial trend (0/100) is the drag.
Buy zoneOvervaluedInd-Swift Laboratories Limited earns a Sell from StocksWizard, with a blended score of 44/100. We put fair value near ₹192.68; at ₹385.35 that leaves roughly 50% downside, so the stock screens overvalued by 50%. On 40.1x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹388.55. Financial health scores 79/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9. It clears 5 of 13 investability checks, with durability 42, valuation 78 and momentum 100 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹154.14. Low-confidence estimate — limited data.
1-year price
EOD · 2026-09-1452-week range
-0.82% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell44Piotroski F-score 2/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 3.2%
- Pass: Low debt (D/E < 0.5): 0.01x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: -67%
- Fail: Earnings growing: -95%
- Fail: Net margin ≥ 10%: 6.5%
- Pass: Current ratio > 1.5: 3.80
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.17
- Fail: Piotroski ≥ 7: 2/9
Shareholding
- Promoter59.4%
- Institutions4.6%
- Public & other35.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Trading near its 52-week high.
- Financially solid — Altman Z 4.17.
Opportunities
- Trading in our value buy zone versus sector peers.
Bear case
Weaknesses
- Low return on equity (3.2%).
- Weak Piotroski score (2/9).
Threats
- Earnings contracting year on year.
- Trades ~50% above our estimated fair value.
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients, intermediates, and formulations across multiple therapeutic areas including macrolide antibiotics, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyroidism, analgesic, aromatase inhibitor, and nootropic treatments. The company operates in India and internationally.
Ind-Swift Laboratories Limited — frequently asked questions
Is Ind-Swift Laboratories Limited a buy, hold or sell?
StocksWizard currently rates Ind-Swift Laboratories Limited (INDSWFTLAB) a Sell, based on a blended score of 44/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Ind-Swift Laboratories Limited's fair value?
Our blended DCF and relative-valuation model estimates Ind-Swift Laboratories Limited's fair value at about ₹192.68, versus a current price of ₹385.35 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Ind-Swift Laboratories Limited financially healthy?
Ind-Swift Laboratories Limited scores 79/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9.
How has Ind-Swift Laboratories Limited's share price performed?
Ind-Swift Laboratories Limited is up 138% over three months, and last traded at ₹385.35. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.